Enterolactone
Based on 1 Customer Validation
Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.2%
- CAS No.: 78473-71-9
- Formule: C18H18O4
- Masse moléculaire:298.33
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
23.5 μM
Compound: Zerumboneoxide
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by Griess assay
|
[PMID: 30096653] |
Enterolactone (25-75 μM; 48 hours) arrests the growth of MDA-MB-231 breast cancer cells in the ‘S’ phase[1]
Enterolactone (25-75 μM; 15 hours) triggers apoptosis in MDA-MB-231 breast cancer cells via caspase-3 activation[1].
Enterolactone inhibits TGF-β-induced migration of MDA-MB-231 breast cancer cells. Enterolactone inhibits TGF-β-induced invasion of MDA-MB-231 breast cancer cells through ECM. Enterolactone inhibits the TGF-β-induced EMT program in MDA-MB-231 breast cancer cells. Enterolactone reduces the formation of actin stress fibers by inhibiting the expression of CD44 and MAPK-p38. Enterolactone inhibits the ERK/NF-κB/Snail signaling pathway to revert TGF-β-induced EMT in MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:25, 50, 75 μM
-
Incubation Time:48 hours
-
Result:There was a non-significant increase (~24%) in the S phase population following treatment with 25 μM EL, whereas there were significant increases (~34% and ~39%) following treatment with 50 and 75 μM EL, respectively.
Chemical Information
-
CAS No. 78473-71-9
-
Appearance Solid
-
Masse moléculaire 298.33
-
Formule C18H18O4
-
Color White to off-white
-
SMILES
O=C1OC[C@H](CC2=CC=CC(O)=C2)[C@H]1CC3=CC=CC(O)=C3
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 30 mg/mL (100.56 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Bigdeli B, et al. Enterolactone: A novel radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis. Toxicol Appl Pharmacol. 2016;313:180-194. [Content Brief]
[2]. Mali AV, et al. Enterolactone modulates the ERK/NF-κB/Snail signaling pathway in triple-negative breast cancer cell line MDA-MB-231 to revert the TGF-β-induced epithelial-mesenchymal transition. Cancer Biol Med. 2018;15(2):137-156. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3520 mL | 16.7600 mL | 33.5199 mL | 83.7998 mL |
| 5 mM | 0.6704 mL | 3.3520 mL | 6.7040 mL | 16.7600 mL | |
| 10 mM | 0.3352 mL | 1.6760 mL | 3.3520 mL | 8.3800 mL | |
| 15 mM | 0.2235 mL | 1.1173 mL | 2.2347 mL | 5.5867 mL | |
| 20 mM | 0.1676 mL | 0.8380 mL | 1.6760 mL | 4.1900 mL | |
| 25 mM | 0.1341 mL | 0.6704 mL | 1.3408 mL | 3.3520 mL | |
| 30 mM | 0.1117 mL | 0.5587 mL | 1.1173 mL | 2.7933 mL | |
| 40 mM | 0.0838 mL | 0.4190 mL | 0.8380 mL | 2.0950 mL | |
| 50 mM | 0.0670 mL | 0.3352 mL | 0.6704 mL | 1.6760 mL | |
| 60 mM | 0.0559 mL | 0.2793 mL | 0.5587 mL | 1.3967 mL | |
| 80 mM | 0.0419 mL | 0.2095 mL | 0.4190 mL | 1.0475 mL | |
| 100 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.8380 mL |
Enterolactone Related Classifications
HY-108692 Related Classifications
Powered by Bioz